Cancer is a heterogeneous disease, both genotypically and phenotypically, but the ability to combine genotype-phenotype relationships at the single-cell level has remained a challenge for researchers.
Instead, researchers have relied on bulk measurements from multiple different assays to piece together information for clinical samples.
Mission Bio, in partnership with BioLegend, has demonstrated a commercially available wet-lab validated protein panel that works specifically with the Tapestri Platform to simultaneously measure DNA variations for up to 1,000 targets and protein expression for 45 targets in thousands of single cells. This novel capability has the power to reveal cell identities and subtle cell states and link genomic variation to protein expression, leading to more informed research on disease and therapeutic development.
Offered Free by: MissionBio
See All Resources from: MissionBio